Fluidigm (FLDM) Tops Q1 EPS by 39c

Fluidigm (NASDAQ: FLDM) reported Q1 EPS of $0.25, $0.39 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $32.79 million versus the consensus estimate of $31.97 million.

“We delivered solid performance in the quarter as we worked to transform our microfluidics and mass cytometry franchises into durable growth platforms,” said Chris Linthwaite, President and CEO. “Fundamental changes in our traditional markets will enable us to focus on next-generation health care decision tools, generate higher recurring revenues and capitalize on a significant addressable market opportunity. We are acting with urgency to cultivate new revenue streams and partnerships in our core markets as vaccinations increase and the demand for COVID testing and related revenue wanes.

“With new publications, new data and expansion into new markets, our mass cytometry business has become increasingly important for health care decision making. Looking ahead, we expect that customers will continue to recognize the numerous translational and clinical research applications of our comprehensive platform.

“Our Vision 2025 strategy focuses on innovation, establishing and mobilizing new markets and channels and seeking collaborations to deliver enhanced value for our customers and stockholders,” continued Linthwaite. “We are confident that our flexibility, efficiency, scalability and novel testing strategies position us well for the future.”

For earnings history and earnings-related data on Fluidigm (FLDM) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• First Merchants Corp (FRME) Tops Q1 EPS by 3c
• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance